OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
OSR Holdings (NASDAQ: OSRH) appointed Dr. Andreas Niethammer as CEO of Vaximm AG, effective December 1, 2025. Dr. Niethammer is Vaximm's scientific co-founder and will lead the company’s oral T‑cell immunotherapy programs, including lead candidate VXM01, which advanced into first‑in‑human studies for pancreatic cancer and glioblastoma and established proof‑of‑concept for oral vector‑based targeting of tumor vasculature.
Under his leadership Vaximm will pursue a forthcoming strategic collaboration to combine its anti‑angiogenic immune activation platform with viral oncolysis technologies that have shown PoC in a completed U.S. FDA Phase 2a study, targeting renal cell carcinoma and other advanced solid tumors.
OSR Holdings (NASDAQ: OSRH) ha nominato il dottor Andreas Niethammer come CEO di Vaximm AG, con effetto 1 dicembre 2025. Il dottor Niethammer è co-fondatore scientifico di Vaximm e guiderà i programmi di immunoterapia orale a cellule T dell'azienda, compreso il candidato di punta VXM01, che è avanzato in studi sull'uomo per cancro pancreatico e glioblastoma e ha stabilito una prova di concetto per la targeting orale basata su vettori della vascolarizzazione tumorale.
Sotto la sua guida, Vaximm perseguirà una prossima collaborazione strategica per combinare la sua piattaforma di attivazione immunitaria anti-angiogenica con tecnologie di oncolisi virale che hanno dimostrato PoC in uno studio completato Fase 2a FDA degli Stati Uniti, mirato al carcinoma renale e ad altri tumori solidi avanzati.
OSR Holdings (NASDAQ: OSRH) nombró al Dr. Andreas Niethammer como CEO de Vaximm AG, con efecto el 1 de diciembre de 2025. El Dr. Niethammer es cofundador científico de Vaximm y dirigirá los programas de inmunoterapia oral de células T de la empresa, incluido el candidato líder VXM01, que avanzó a estudios en humanos iniciales para cáncer de páncreas y glioblastoma y estableció una prueba de concepto para la orientación oral basada en vectores de la vasculatura tumoral.
Bajo su liderazgo, Vaximm buscará una próxima colaboración estratégica para combinar su plataforma de activación inmune antiangiogénica con tecnologías de oncolisis viral que han mostrado PoC en un estudio de Fase 2a de la FDA de Estados Unidos finalizado, orientado al carcinoma de células renales y a otros tumores sólidos avanzados.
OSR Holdings (NASDAQ: OSRH) 은 Vaximm AG의 CEO로 Dr. Andreas Niethammer 를 임명했으며, 효력은 2025년 12월 1일 부터입니다. Niethammer 박사는 Vaximm의 과학적 공동 창립자이며 회사의 경구용 T세포 면역요법 프로그램을 이끌고, 선두 후보인 VXM01은 췌장암과 뇌종양교모세포종에 대한 최초 인간 대상 연구로 진입했고, 종양 혈관화를 표적으로 하는 경구 벡터 기반의 개념 증명을 확립했다고 합니다. 그의 지도하에 Vaximm은 반혈관생성 면역 활성화 플랫폼과 바이러스성 종양용해 기술을 결합하는 전략적 협력을 추구할 것이며, 이 기술들은 미국 FDA의 2a상 시험을 완료한 PoC를 보였으며, 신장세포암 및 기타 고도 진행된 고형 종양을 대상으로 합니다.
OSR Holdings (NASDAQ: OSRH) a nommé le Dr Andreas Niethammer comme PDG de Vaximm AG, à effet au 1er décembre 2025. Le Dr Niethammer est le co-fondateur scientifique de Vaximm et dirigera les programmes d’immunothérapie par cellules T orales de l’entreprise, y compris le candidat phare VXM01, qui est passé en essais chez l’homme pour le cancer du pancréas et le glioblastome et a établi une preuve de concept pour le ciblage oral basé sur des vecteurs de la vasculature tumorale. Sous sa direction, Vaximm poursuivra une prochaine collaboration stratégique visant à combiner sa plateforme d’activation immunitaire anti-angiogénique avec des technologies d’oncolyse virale qui ont montré un PoC dans une étude de phase 2a de la FDA américaine, ciblant le carcinome rénal et d’autres tumeurs solides avancées.
OSR Holdings (NASDAQ: OSRH) ernannte Dr. Andreas Niethammer zum CEO von Vaximm AG, mit Wirkung zum 1. Dezember 2025. Dr. Niethammer ist wissenschaftlicher Mitgründer von Vaximm und wird die Oral-T-Zell-Immuntherapie-Programme des Unternehmens leiten, einschließlich des führenden Kandidaten VXM01, der in Erste-Menschen-Studien für Bauchspeicheldrüsenkrebs und Glioblastom vorgerückt ist und einen Beweis der Konzeption für die orale vektorbasierte Zielgerichtung der Tumorvasculatur erbracht hat. Unter seiner Führung wird Vaximm eine kommende strategische Zusammenarbeit anstreben, um seine Plattform zur antiangiogenen Immunaktivierung mit Technologien der viralen Onkolyse zu verbinden, die PoC in einer abgeschlossenen FDA Phase-2a-Studie gezeigt haben, mit Fokus auf das Nierenzellkarzinom und andere fortgeschrittene solide Tumore.
OSR Holdings (NASDAQ: OSRH) عينت الدكتور Andreas Niethammer كـ الرئيس التنفيذي لـ Vaximm AG، اعتباراً من 1 ديسمبر 2025. الدكتور Niethammer هو المؤسس العلمي المشارك لـ Vaximm وسيركّز على برامج immunotherapy الذاتي الفموي على خلايا T للشركة، بما في ذلك المرشح الرائد VXM01، الذي تقدم إلى دراسات بشرية أولية لأمراض السرطان البنكرياس والورم الدبقي ويثبت دليل المفهوم لاستهداف الوريد الأساسي بواسطة ناقلات فموية. وتحت قيادته ستسعى Vaximm إلى تعاون استراتيجي مقبل لدمج منصتها لإطلاق المناعة المضادة للنجارة مع تقنيات التحلل الورمي الفيروسي التي أظهرت PoC في دراسة FDA المرحلة 2a الأمريكية مكتملة، تستهدف سرطان الخلايا الكلوية وأورام صلبة متقدمة أخرى.
- CEO appointment effective December 1, 2025
- VXM01 advanced to first‑in‑human studies with PoC in pancreatic cancer and glioblastoma
- Planned strategic collaboration with oncolytic technology with completed U.S. FDA Phase 2a PoC
- None.
Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the concept of oral T-cell vaccination in a landmark Nature publication (2002). Under his leadership, Vaximm advanced its lead therapeutic vaccine, VXM01, which targets VEGFR-2, into first-in-human clinical studies for pancreatic cancer and glioblastoma, establishing proof-of-concept for oral vector-based immunotherapy targeting tumor vasculature.
Advancing Combination Immuno-Oncology
Under Dr. Niethammer's leadership, Vaximm will focus on integrating its anti-angiogenic immune activation platform with complementary viral oncolysis technologies that have already achieved clinical proof-of-concept (PoC) in a completed
"I am delighted to step into the role of CEO as we enter an exciting new phase where Vaximm's oral vaccination platform can be combined with potent oncolytic and immune-modulating approaches," said Dr. Niethammer. "Our goal is to deliver more durable systemic antitumor responses while maintaining an excellent safety and tolerability profile."
"As the inventor of Vaximm's core platform, Dr. Niethammer uniquely combines scientific vision with deep clinical development experience," said Peter Hwang, CEO of OSR Holdings. "His appointment as Vaximm CEO marks a natural progression as we prepare for the next chapter of scientific innovation and strategic partnerships to accelerate the development of transformative therapies."
About Vaximm AG
Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell vaccination platform harnesses live, attenuated bacterial vectors to deliver tumor-associated antigens, inducing robust cellular immune responses. Lead candidate VXM01, targeting VEGFR-2, has demonstrated clinical activity and safety in multiple cancer indications.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes. Learn more at www.OSR-Holdings.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-appoints-scientific-co-founder-dr-andreas-niethammer-as-chief-executive-officer-of-vaximm-ag-to-lead-next-phase-of-immuno-oncology-expansion-302615840.html
SOURCE OSR Holdings
FAQ
When does Dr. Andreas Niethammer become CEO of Vaximm (OSRH)?
What is Vaximm's lead candidate and which cancers has it entered human studies for (OSRH)?
What strategic focus will Vaximm pursue under the new CEO (OSRH)?
Has Vaximm reported clinical proof‑of‑concept for its approaches (OSRH)?
Will OSR Holdings announce the collaboration details and timing (OSRH)?
What tumors are targeted by the planned Vaximm collaboration (OSRH)?
